Drug Approval | February 21, 2025
USFDA issues Form-483 for Piramal Pharma's facility at Turbhe
Observations are largely around improvement of procedures and practices
Observations are largely around improvement of procedures and practices
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The Alathur facility specializes in the production of Cephalosporin antibiotics
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Subscribe To Our Newsletter & Stay Updated
